BioNTech SE (BNTX) Financials: History & Chart

BioNTech SE (BNTX)BNTXBioNTech SE

About BioNTech SE

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

Mainz, RP

7,807 employees

www.biontech.de

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ugur Sahin

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	3.28B	138.69M	1.06B	1.78B	307.40M	197.69M	1.23B	1.39B	137.85M
Cost of Goods Sold	878.17M	226.29M	387.82M	174.01M	90.05M	90.63M	252.14M	199.20M	64.05M
Gross Profit	2.41B	-87.60M	668.01M	1.61B	217.35M	107.07M	980.09M	1.19B	73.80M
Gross Profit Margin	73.3%	-63.2%	63.3%	90.2%	70.7%	54.2%	79.5%	85.6%	53.5%
Total Operating Expenses	4.10B	688.74M	938.89M	1.66B	807.99M	684.68M	826.22M	1.18B	1.11B
Research & Development	2.50B	654.10M	588.07M	662.71M	600.07M	568.42M	633.51M	612.73M	626.15M
Selling, General & Administrative	853.04M	174.22M	342.63M	174.24M	161.95M	130.43M	136.79M	167.57M	196.86M
Operating Income (EBIT)	-1.69B	-776.34M	-270.88M	-55.03M	-590.64M	-577.61M	153.87M	11.69M	-1.03B
Operating Margin	-51.5%	-559.8%	-25.7%	-3.1%	-192.1%	-292.2%	12.5%	0.8%	-750.7%
Income Before Tax (EBT)	-1.38B	-667.13M	-264.60M	28.98M	-474.65M	-481.69M	311.89M	176.70M	-863.08M
Interest Income	378.01M	72.46M	305.55M	N/A	N/A	N/A	N/A	N/A	180.18M
Interest Expense	16.61M	4.70M	7.56M	468K	3.88M	6.73M	N/A	5.80M	7.84M
Other Income/Expense	315.49M	109.21M	6.28M	84.01M	115.98M	95.93M	158.02M	165.01M	171.80M
Net Income	-1.47B	-624.62M	-354.89M	-33.68M	-455.68M	-449.68M	268.71M	220.57M	-865.22M
Income Tax Expense	91.46M	-42.51M	90.29M	62.66M	-18.98M	-32.01M	43.18M	-43.87M	2.14M
Net Profit Margin	-44.7%	-450.4%	-33.6%	-1.9%	-148.2%	-227.5%	21.8%	15.9%	-627.7%
EBITDA	-1.15B	-633.90M	-79.12M	90.70M	-530.52M	-531.33M	325.14M	61.13M	-981.43M
EBITDA Margin	-35.1%	-457.1%	-7.5%	5.1%	-172.6%	-268.8%	26.4%	4.4%	-712.0%
Depreciation & Amortization	540.05M	142.44M	191.76M	145.73M	60.11M	46.29M	171.27M	49.44M	53.45M
EPS Basic	-5.94	-2.47	-1.44	-0.14	-1.89	-1.87	1.12	0.92	-3.66
EPS Diluted	-5.94	-2.47	-1.44	-0.14	-1.89	-1.87	1.12	0.90	-3.66
Shares Outstanding	252.88M	252.88M	245.16M	239.17M	241.63M	240.35M	240.28M	239.74M	237.73M
Diluted Shares Outstanding	252.88M	252.88M	245.16M	239.17M	241.63M	240.35M	240.28M	244.57M	237.73M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	3.24B	2.85B	4.22B	18.52B	21.60B	589.16M	121.87M	146.01M
Cost of Goods Sold	724.10M	560.51M	662.03M	3.20B	3.31B	72.44M	19.53M	15.67M
Gross Profit	2.51B	2.29B	3.55B	15.32B	18.29B	516.72M	102.35M	130.34M
Gross Profit Margin	77.6%	80.3%	84.3%	82.7%	84.7%	87.7%	84.0%	89.3%
Total Operating Expenses	3.25B	3.65B	2.79B	1.79B	889.51M	617.38M	306.03M	191.97M
Research & Development	2.37B	2.33B	1.97B	1.64B	1.08B	787.91M	254.19M	163.74M
Selling, General & Administrative	820.10M	620.26M	615.56M	579.05M	372.47M	132.54M	48.59M	30.98M
Operating Income (EBIT)	-732.79M	-1.36B	762.03M	13.53B	17.40B	-100.66M	-203.68M	-61.63M
Operating Margin	-22.6%	-47.8%	18.1%	73.0%	80.5%	-17.1%	-167.1%	-42.2%
Income Before Tax (EBT)	-1.19B	-701.75M	1.31B	13.86B	17.13B	-178.10M	-201.33M	-54.55M
Interest Income	296.27M	N/A	387.76M	50.68M	1.78M	1.78M	1.97M	2.36M
Interest Expense	16.02M	13.63M	8.57M	16.93M	6.41M	2.28M	1.90M	2.03M
Other Income/Expense	-452.76M	659.19M	547.13M	333.18M	-270.24M	-77.45M	2.36M	7.09M
Net Income	-1.28B	-688.91M	1.03B	10.09B	11.72B	18.57M	-200.99M	-54.96M
Income Tax Expense	96.24M	-12.84M	282.34M	3.77B	5.41B	-196.67M	-224K	687K
Net Profit Margin	-39.6%	-24.2%	24.4%	54.5%	54.2%	3.2%	-164.9%	-37.6%
EBITDA	-300.90M	-1.05B	964.46M	13.66B	17.48B	-53.38M	-165.64M	-36.47M
EBITDA Margin	-9.3%	-36.9%	22.9%	73.7%	80.9%	-9.1%	-135.9%	-25.0%
Depreciation & Amortization	431.89M	308.58M	202.43M	131.92M	85.60M	47.27M	38.04M	25.16M
EPS Basic	-5.30	-2.87	4.27	40.74	49.94	0.07	-0.95	-0.24
EPS Diluted	-5.30	-2.87	4.23	39.68	46.91	0.07	-0.95	-0.24
Shares Outstanding	241.70M	240.40M	240.60M	243.30M	244.00M	235.44M	211.50M	226.86M
Diluted Shares Outstanding	241.70M	240.40M	242.70M	249.80M	259.70M	248.53M	211.50M	226.86M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.